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1. Introduction 
Sleep disturbances are common problems in patients with Parkinson’s disease (PD) caused 
by various factors including nocturnal motor symptoms, psychiatric symptoms, dementia, 
medication use and circadian cycle disruptions as well as comorbidity with sleep apnea 
syndrome (SAS), restless legs syndrome (RLS) and rapid eye movement sleep behavior 
disorder (RBD) (Table 1). As impaired sleep quality and sleep fragmentation due to 
nighttime problems are associated with daytime motor dysfunction and have a negative 
impact on the quality of life of the patient (Gómez-Esteban et al., 2010), an intensive and 
detailed evaluation of nighttime problems is warranted. Patients often may be unaware of 
sleep disturbances and even neurologists have been reported to fail to recognize sleep 
disorders in approximately 40% of PD patients (Shulman et al., 2002). Here, we review sleep 
disorders in patients with PD, mainly focusing on nighttime problems. 
2. Sleep disturbances related to Parkinson’s disease itself 
Impaired sleep architecture and sleep-wakefulness systems are observed in PD as disease 
related changes. Insomnia in patients with the early stage of disease or in untreated patients 
may be associated with disease-related sleep disturbances rather than sleep disturbances 
caused by other factors including motor dysfunction, medication use, neuropsychiatric 
symptoms and cognitive dysfunction, though non-motor symptoms can occur in the early 
phase of the disease. Polysomnography (PSG) recordings yield altered sleep structure that is 
characterized by a reduction in The percentage of slow wave sleep and a decrease in the 
amount of REM sleep (Petit et al., 2004) caused by the degeneration of cholinergic neurons 
in the basal forebrain, noradrenergic neurons in the locus ceruleus and serotoninergic 
neurons in the raphe nucleus (N.J.  Diederich & Comella, 2003).  
Serotonin, acetylcholine and noradrenalin play a role in maintaining wakefulness, and thus, 
disturbances lead to excessive daytime sleepiness. In some patients with PD, excessive 
daytime sleepiness and sudden onset of sleep episodes have been associated with a short sleep 
latency and sleep onset REM period recorded by the multiple sleep latency test (Arnulf et al., 
2002). Similar features are observed in narcolepsy, a sleep disorder characterized by severe 
daytime sleepiness caused by loss of orexin neurons. Loss of orexinergic neurons in the 
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posterior portion of the lateral hypothalamus (Fronczek et al., 2007) and the reduction of the 
A10 dopaminergic group in the ventral tegmental area (Rye, 2004) have also been implicated 
in impaired wakefulness in PD. Further study is required to examine whether impairment of 
the orexin system accounts for excessive daytime sleepiness in PD and whether decreased 
orexin levels reflect disease-related changes or secondary compensatory changes resulting 
from dopaminergic dysfunctions (Baumann et al., 2008; Compta et al., 2009). 
 
Impairment of sleep architecture 
Involvement of the cholinergic, serotoninergic and noradrenergic systems  
reduces REM and slow-wave sleep 
Impairment of the arousal system (orexin, serotonin, noradrenalin, acetylcholine and
dopamine) 
Nocturnal motor symptoms 
(wearing-off phenomenon, rigidity, akinesia, tremor, medication-related dyskinesia and 
dystonia) 
Psychiatric symptoms including depression and psychosis 
Nightmares and vivid dreams 
Hallucinations 
Cognitive dysfunction 
Nocturia 
Pain 
Medication use 
Sleep apnea syndrome 
REM sleep behavior disorder 
Restless legs syndrome 
Periodic limb movement disorder 
Table 1. Multifactorial causes associated with sleep disorders in PD 
3. Dopamine and sleep 
Dopamine has a role in regulating the sleep-wake cycle (Rye & Jankovic, 2002). Biphasic 
effects of dopaminergic stimulation on sleep have been reported based on animal studies. 
High doses of D2 agonists reduce slow-wave sleep and REM sleep and increase wakefulness 
mediated via postsynaptic receptors, whereas low doses of D2 stimulants increase slow 
wave sleep and induce sleep mediated via presynaptic receptors (Monti et al., 1988). A D1 
receptor agonist suppresses the amount of REM sleep in dose-dependent manner and 
enhanced wakefulness, while D1 antagonists increase REM sleep (Trampus et al., 1991). The 
study by Qu et al. examined the mechanism by which modafinil increases wakefulness. 
They found that the pretreatment of D2 receptor knockout mice with a D1 receptor 
antagonist completely abolished the arousal effects of modafinil, strongly indicating that 
dopaminergic D1 and D2 receptors are essential for the wakefulness induced by modafinil 
(Qu et al., 2008). The involvement of dopamine systems in the mesocorticolimbic and striatal 
systems in conjunction with dopaminergic therapy further complicates the role of dopamine 
in PD sleep disturbances. 
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4. Nocturnal motor problems 
Nocturnal disturbances have been reported in up to 98% of patients with PD (Lees et al., 
1988). Disturbances include rigidity, tremor, dystonia, akinesia, nightmares, 
hallucinations, muscle cramps and nocturia. These symptoms result in frequent nocturnal 
awakenings that contribute to sleep maintenance insomnia, a common form of insomnia 
in PD (Chaudhuri et al., 2002; Factor et al., 1990; Lees et al., 1988; Suzuki et al., 2007; 
Tandberg et al., 1998). Sleep onset insomnia can be seen in PD, but it does not seem to 
account for the majority of insomnia in PD when compared with age-matched controls. In 
a community-based sleep study, sleep onset insomnia, sleep maintenance insomnia and 
early awakening were observed in 31.8%, 38.9% and 23.4% of PD patients compared with 
22%, 12% and 11% of healthy controls, respectively (Tandberg et al., 1998). The frequency 
of sleep onset insomnia was not significantly different between the groups. Identification 
of the nature of nocturnal motor symptoms and the appropriate treatment (e.g., an 
increase or reduction in the amount of dopaminergic drugs) can improve nocturnal 
disturbances. A further tool is necessary for assessing nighttime disabilities related to PD. 
Although PSG is considered to be the gold standard in the assessment of sleep disorders 
because it provides information about the patient’s actual sleep status, including sleep 
efficiency, sleep latency and sleep structure and can detect SAS, RBD or RLS, several 
questionnaires have been developed to address insomnia or daytime sleepiness in the 
general population (the Pittsburgh Sleep Quality Index, or the Epworth sleepiness scale, 
ESS) (Buysse et al., 1989; Johns, 1991). 
4.1 Parkinson’s disease sleep scale 
Chaudhuri et al. developed the Parkinson’s disease sleep scale (PDSS) (Chaudhuri et al., 
2002), a visual analogue scale that assesses 15 PD-related nocturnal symptoms of nocturnal 
disability in PD. This scale is now regarded as a recommended, reliable scale (Högl et al., 
2010). The scale includes the following: overall quality of night’s sleep (item 1); sleep onset 
and maintenance insomnia (items 2 and 3); nocturnal restlessness (items 4 and 5); nocturnal 
psychosis (items 6 and 7); nocturia (items 8 and 9); nocturnal motor symptoms (items 10-13); 
sleep refreshment (item 14); and daytime dozing (item 15). It has been validated and used 
extensively in a number of countries with high reliability (Abe et al., 2005; Margis et al., 
2009; Martinez-Martin et al., 2004; Suzuki et al., 2007; Wang et al., 2008). Their study found 
that patients with advanced disease had more severe nocturnal disabilities when compared 
to patients with early or moderate disease. Our multicenter study also revealed more severe 
nocturnal disturbances measured by PDSS in patients with advanced PD [Hoehn & Yahr 
(H&Y), stage IV] when compared to those with early and moderate PD (H&Y, stages I –III). 
The characteristics of sleep disturbances in PD were distinguishable from that in the control 
subjects (Figure 1A and B). Sleep disturbances were associated with disease duration, 
depressive symptoms and complications with dopaminergic treatment (dyskinesia and 
wearing off) (Suzuki et al., 2007). However, it has been shown that although nocturnal 
symptoms assessed by PDSS, such as nocturia, nighttime cramp, dystonia and tremor, were 
more severe in advanced PD patients, they could also be observed in untreated or early 
stage PD patients when compared with control subjects (Dhawan et al., 2006). This suggests 
that nocturnal disturbances can develop in the early stages of PD, even when the patients 
are untreated and exhibit only mild motor symptoms. Thus, nocturnal problems can be 
treated with dopaminergic treatments. 
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Fig. 1A. Profiles of the mean PDSS scores of each item according to the stage of the disease 
as defined by H&Y. There were highly significant differences between H&Y Stage 4 and 
H&Y Stages 1-3 for item 3 (sleep maintenance insomnia), item 6 (distressing dreams at 
night), item 11 (painful muscle cramp) and item 15 (falling asleep unexpectedly). 
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Fig. 1B. Profiles of mean PDSS scores for each item in PD and control patients. The most 
severe ratings in both groups were found for sleep maintenance insomnia (item 3) and 
nocturia (item 8). With the exception of item 2 (sleep onset insomnia), item 11 (painful 
muscle cramp) and item 14 (tiredness and sleepiness after waking in the morning), PDSS 
scores of patients with PD were significantly lower when compared to healthy subjects.  
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4.2 Parkinson’s disease sleep scale-2 
Importantly, the PDSS does not screen for sleep apnea syndrome (SAS). Recently, a 
modified version of PDSS, PDSS-2, has been published and is shown to have excellent 
validity and reliability (Trenkwalder et al., 2011b). The item regarding unexpected daytime 
sleepiness was removed because it can be caused by numerous factors in PD, and a new 
item to screen for SAS was added. Three aspects of sleep problems can be obtained by factor 
analysis: sleep-specific disturbance, such as sleep onset and the maintenance insomnia, 
unrestored sleep in the morning, getting up to pass urine and the overall quality of sleep; 
PD-specific nocturnal motor symptoms at night, such as akinesia, early morning dystonia, 
tremor during waking periods at night, periodic limb movements, restless behavior and 
motor symptoms probably due to RBD; and PD-specific nocturnal non-motor symptoms, 
such as hallucinations, confused states, pain, difficulty breathing with snoring and 
immobility.  A recent study assessing the effect of rotigotine, a non-ergot dopamine agonist 
with 24-hour transdermal delivery, on early morning motor function and sleep have shown 
that rotigotine administration improved motor abilities as assessed by the Unified Parkinson 
Disease Rating Scale (UPDRS) motor score and sleep problems as assessed by PDSS-2 
(Trenkwalder et al., 2011a). In clinical practice, the use of both ESS and PDSS-2 would be 
useful for assessing daytime sleepiness and nighttime problems in PD.  
5. Motor symptoms at night 
Importantly, disabling motor symptoms, such as akinesia, resting tremor and rigidity, occur 
not only during the daytime but also during the nighttime. Patients in the advanced stages 
of the disease are likely to have motor dysfunction throughout the day, but some patients, 
especially those in the early stages of the disease, may predominantly have nighttime motor 
problems (Dhawan et al., 2006). This is supported by the results of several studies showing a 
weak or nonexistent correlation between sleep disturbances and daytime motor symptoms 
(UPDRS motor score) (Chaudhuri & Martinez-Martin, 2004; Tandberg et al., 1998) and no 
correlation between nocturnal motor symptoms obtained by PDSS-2 and UPDRS motor 
score (Trenkwalder et al., 2011b). Kumar et al., however, found a patient’s UPDRS motor 
score to be a significant determinant of sleep disturbances (Kumar et al., 2002).  
Nocturnal motor symptoms can result in frequent awakenings at night, which sometimes 
can contribute to daytime sleepiness. In our previous study, however, PD patients with 
excessive daytime sleepiness (ESS ≥ 10) had similar PDSS scores, except for falling asleep 
unexpectedly (item 15), when compared to those without excessive daytime sleepiness (ESS 
< 10), suggesting that excessive daytime sleepiness is more related to disease related 
changes and dopaminergic medication use than nocturnal disturbances (Suzuki et al., 2008). 
When wearing off-related motor symptoms or the worsening of motor symptoms during the 
night are significant problems for a patient, providing continuous dopaminergic stimulation 
via a long-acting dopamine agonist at nighttime (Pahwa et al., 2007; Poewe et al., 2007), 
deep brain stimulation (Arnulf et al., 2000) or an overnight subcutaneous infusion of 
apomorphine (Reuter et al., 1999) has been reported to be beneficial. For hallucinations, 
psychosis or medication-related dyskinesia at night, however, reductions in the dose of 
dopaminergic agents and/or the addition of atypical antipsychotics may help. Amantadine 
or selegiline can cause frequent nocturnal awakenings, and reducing the dose or changing 
the time of the administration of these drugs to the morning may reduce nocturnal 
awakening.   
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6. Nocturia 
Urinary bladder related symptoms, such as frequency, urgency and urge incontinence, are 
common in PD and can cause frequent nocturnal awakenings. Although nocturia is 
associated with the normal aging process, 80% of PD patients have had two or more 
episodes of nocturia per night that were caused by overflow incontinence and a spastic 
bladder (Lees et al., 1988). These symptoms are attributable to diffuse autonomic 
dysfunction in PD. Lewy bodies can be found in autonomic regulatory regions, including 
the hypothalamus, sympathetic (intermediolateral nucleus of the thoracic cord and 
sympathetic ganglia), and parasympathetic nervous systems (dorsal, vagal, and sacral 
parasympathetic nuclei) (Micieli et al., 2003). Furthermore, the emergence of lesions in the 
dorsal vagus nucleus and in other autonomic braintstem centers has been found before the 
manifestation of motor symptoms related to pathological changes in the substantia nigra 
(Braak et al., 2003).  
Dopaminergic mechanisms also play a role in normal bladder control and overactive 
bladder. In animal studies, the stimulation of D1 receptors inhibits the micturition reflex, 
while the stimulation of D2 receptors facilitates the micturition reflex. Therefore, D2 
depletion of dopaminergic neurons induces overactive bladder and D1 receptor agonists 
produce a dose dependent inhibition of the micturition reflex (Winge & Fowler, 2006). In PD 
models, the beneficial effect of concurrent activation of D1/D2 receptors rather than 
selective stimulation of D2 receptors has been reported (Yoshimura et al., 1998). Kuno et al. 
reported that switching from bromocriptine to pergolide improved nocturia, thereby 
improving sleep status in patients with PD (Kuno et al., 2004). Anticholinergic drugs, such 
as oxybutinin and tolterodine, are commonly used for detrusor hyperreflexia. The beneficial 
effect of subthalamic deep brain stimulation on detrusor hyperreflexia has been reported 
(Seif et al., 2004). When nocturia is related to wearing off symptoms, changing medications 
to a long-acting dopamine agonist before bedtime can be beneficial. A urologic examination 
is recommended to rule out underlying urologic diseases. 
7. Pain 
Pain has been reported in approximately 60% of PD patients (Barone et al., 2009) and is 
associated with sleep disorders and depressive symptoms (Goetz et al., 1987; Starkstein et 
al., 1991), in addition to tremor, rigidity, akinesia, dystonia and akathisia. A recent review 
classified pain into the following categories: musculoskeletal pain, radicular or neuropathic 
pain, dystonia-related pain, akathitic discomfort and primary central parkinsonian pain 
(Ford, 2010). Pain is thought to be mediated through medial and lateral pain pathways. 
However, the pathophysiology of pain perception is not yet well understood. The basal 
ganglia appear to have an important role for the relay of nociceptive information within the 
striatum and limbic system (Ford, 2010), and dopamine has been implicated in endogenous 
pain modulation systems (Potvin et al., 2009). Nocturnal pain is related to nocturnal 
awakening but not to all sleep disorders. Primary central parkinsonian, akathitic and 
dystonia-related pain may respond to dopaminergic treatment, and painful symptoms can 
worsen during wearing off periods. Thus, the appropriate evaluation of pain-related 
symptoms and managing wearing off-related symptoms during nighttime can improve 
pain-related sleep disturbances.   
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8. Hallucinations and psychosis  
Hallucinations and psychosis affect 30 to 45% of PD patients treated with levodopa for a 
long period (Goetz, 1999). Among a wide spectrum of hallucinations, visual hallucinations 
are commonly seen. Sleep disturbances, daily doses of levodopa, older age, depression and 
cognitive impairment have been shown to increase the risk for hallucinations in PD patients 
(Goetz, 2010; Nausieda et al., 1982). A single photon emission computed tomography 
imaging study showed that PD patients with visual hallucinations had perfusion reductions 
in the bilateral inferior parietal lobule, inferior temporal gyrus, precuneus gyrus and 
occipital cortex (Matsui et al., 2006). A ten-year longitudinal study of sleep disorders and 
hallucinations in PD showed that visual hallucinations were associated with concurrent 
nightmares, vivid dreams and severe sleep fragmentation. At baseline, no sleep 
abnormalities at study entry predicted future development of hallucinations in PD patients 
not currently experiencing hallucinations (Goetz et al., 2010). When reductions in 
dopaminergic treatments are ineffective, administration of antipsychotics should be 
considered.  
9. Depressive symptoms and nocturnal disturbances 
A close link between depression and sleep disorders has been reported in PD (Borek et 
al., 2006; Happe et al., 2001). Both have a negative impact on the quality of life in PD 
patients (Gómez-Esteban et al., 2010; Rahman et al., 2008). In a recent systematic review, 
the prevalence of depression in PD patients varies, ranging from 2.7% to 89% (Reijnders 
et al., 2008). However, the exact details of nocturnal symptoms that contribute to 
depression in PD are not well studied. In our multi-center study, depressive symptoms 
(Zung Self-Rating Depression Scale, SDS score ≥ 40) were present in 64.9% of PD 
patients, and SDS scores were strongly correlated with PDSS scores (Figure 2A) (Suzuki 
et al., 2009). Using a regression model, PDSS scores and UPDRS Part I (mental state) 
were significant determinants of depressive symptoms. However, depressed PD patients 
showed greater disease severity and more severe motor dysfunction than non-depressed 
PD patients. Similarly, Chaudhuri and Martinez-Martin reported a significant correlation 
between PDSS score and depressive symptoms (Chaudhuri & Martinez-Martin, 2004). 
Compared to patients without depressive symptoms and controls, patients with 
depressive symptoms had significantly impaired scores in almost all PDSS items except 
item 2 (difficulty in initiating sleep) and item 11 (painful muscle clamp) (Figure 2B). 
Surprisingly, there were no significant differences between controls and non-depressed 
patients in PDSS sub-items, suggesting that depressive symptoms play a pivotal role in 
developing nocturnal disturbances. Upon detailed evaluation of nocturnal symptoms, 
early morning tremor and nocturnal dystonia were closely associated with depressive 
symptoms. This result is in line with the finding that depressive symptoms were 
exacerbated during periods of time in which patients experienced nocturnal wearing off-
related (hypodopaminergic state) motor symptoms (Cummings, 1992). While depression 
can trigger motor fluctuations, such as the wearing off phenomenon (Lieberman, 2006). 
Raising awareness of depressive symptoms and the application of appropriate 
management techniques may improve both depression and sleep disorders in PD 
patients. 
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Fig. 2A. Correlation between PDSS total score and SDS score 
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Fig. 2B. Profiles of mean PDSS scores of items in depressed PD (SDS ≥ 40), nondepressed PD 
(SDS < 40) patients and controls.  
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10. REM sleep behavior disorder (RBD) 
REM sleep behavior disorder (RBD) is characterized by a loss of muscle atonia during REM 
sleep, enabling patients to act out dreams, often leading to injuries to themselves or their 
bed partner (Schenck et al., 1986). RBD is likely to affect older individuals and is 
predominantly seen in males (Olson et al., 2000). Animal studies show that lesions of the 
locus coeruleus perialpha in cats and the sublaterodorsal nucleus in rats caused REM sleep 
without atonia and with complex movements (Sastre & Jouvet, 1979). RBD was initially 
thought to be an idiopathic disorder; however, a study in 1996 by Schenck demonstrated 
that 38% of 29 patients with idiopathic RBD developed PD within 3.7 ± 1.4 years (Schenck et 
al., 1996). RBD is associated with neurodegenerative disorders, particularly with 
synucleinopathies, such as PD, multiple system atrophy and dementia with Lewy bodies 
(Olson et al., 2000; Postuma et al., 2009; Stiasny-Kolster et al., 2005). Moreover, nonmotor 
symptoms of PD, such as impaired visual and olfactory discrimination, cardiac sympathetic 
denervation and cognitive impairment, that often precede the onset of motor symptoms 
have been found in idiopathic RBD patients (Gagnon et al., 2006; Miyamoto et al., 2006; 
Miyamoto et al., 2010; Postuma et al., 2010b; Postuma et al., 2006). In RBD, substantia nigra 
hyperechogenicity (Iwanami et al., 2010) and decreased regional cerebral blood flow in the 
parietooccipital and limbic lobes and the cerebellar hemispheres (Hanyu et al., 2011) have 
been found to correspond with alpha syncleinopathies, including PD. As a possible 
prodromal phase of neurodegenerative diseases, a diagnosis of RBD is crucial for early 
intervention. Excessive tonic and phasic EMG activity during REM sleep is increased over 
time in patients with RBD (Iranzo et al., 2009). Postuma et al. reported that the severity of 
REM atonia loss during baseline PSG can predict the development of PD (Postuma et al., 
2010a).  
PD patients with RBD exhibited a nontremor predominant phenotype, increased frequency 
of falls and poor response to dopaminergic medications (Postuma et al., 2008b). However, 
the overall disease severity, quantitative motor testing and motor complications did not 
differ between the PD patients with and without RBD. Additionally, the presence of RBD in 
PD is associated with orthostatic hypotension and impaired color vision but not olfactory 
impairment (Postuma et al., 2008a). Interestingly, restored motor control (movements, 
speech and facial expressions) has been observed in PD and in multiple system atrophy 
patients with RBD during REM sleep (De Cock et al., 2011; De Cock et al., 2007). The 
mechanism for the improvement of parkinsonism during RBD was unclear but may be due 
to enhanced dopamine transmission.  
RBD can be triggered by antidepressants. Clonazepam (0.5 to 1.5 mg) at bedtime is the most 
effective treatment for RBD patients. Melatonin (3-12 mg) at bedtime has been shown to 
ameliorate RBD (Aurora et al., 2010). Administration of 2.5 g of Yi-Gan San, an herbal 
medication, three times a day, alone or in conjunction with 0.25 mg clonazepam, has also 
been reported to be effective in the treatment of RBD (Shinno et al., 2008).  
11. Restless legs syndromes (RLS) 
Restless legs syndrome (RLS) is a sensorimotor disorder associated with an irresistible urge 
to move the legs, causing insomnia. Symptoms get worse at rest and become apparent in the 
evening and at nighttime. Some studies have demonstrated a higher rate of RLS 
comorbidity in PD when compared to the general population (Gómez-Esteban et al., 2007; 
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Peralta et al., 2010), while the other studies found no difference (Calzetti et al., 2009; Loo & 
Tan, 2008). Although the pathophysiology of RLS is unclear, central dopaminergic 
dysfunction has been implicated based on the estimated impairment of A11 dopaminergic 
nuclei in the hypothalamus and a favorable response to a dopamine agonist. This structure 
innervates preganglionic sympathetic neurons and the dorsal horn as well as serotoninergic 
pathways and motor neurons in the spinal cord (Walters & Rye, 2009). Iron deficiency also 
contributes to impairments in dopamine signaling in the brain. Low iron and ferritin levels 
in cerebrospinal fluid have been found in patients with RLS (Mizuno et al., 2005).  
Caffeine, alcohol and some medications, including antihistamines, dopamine antagonists, 
tricyclic antidepressants and serotonergic reuptake inhibitors, can exacerbate or cause RLS 
(Ekbom & Ulfberg, 2009). Iron replacement therapy should be considered when serum 
ferritin levels are lower than 50 µg/L. Dopamine agonists, pramipexole and ropinirole, at 
bedtime are effective treatments for RLS.  
In PD patients, however, nonmotor symptoms related to nondopaminergic systems (e.g., 
cognitive impairment, autonomic dysfunction, depression and sleepiness), but not motor 
symptoms, were found to be associated with RLS (Verbaan et al., 2010). Gómez-Esteban et 
al. found high prevalence of RLS in PD patients but found no difference in disease severity, 
UPDRS scores or quality of life between groups with or without RLS (Gómez-Esteban et al., 
2007). Peralta et al. found a positive association between motor fluctuation, wearing off 
phenomenon, and RLS symptoms in PD patients but suggested wearing off-induced 
restlessness can be an “RLS-mimic” (Peralta et al., 2010).  
Autopsy studies have shown increased substantia nigra iron levels in PD patients (Morris & 
Edwardson, 1994) and decreased substantia nigra iron levels in RLS patients (Connor et al., 
2003). Interestingly, when comparing PD with and without RLS, transcranial sonography 
findings demonstrated that there were no significant differences in SN echogenicity, which 
is considered to reflect the amount of tissue iron content, between the two groups, whereas 
idiopathic RLS patients showed significant substantia nigra hypoechogenicity (Kwon et al., 
2010). This suggests that the pathogenesis of RLS in PD and idiopathic RLS may involve 
different mechanisms.  
12. Sleep apnea syndrome (SAS) 
Previous studies reported a high incidence (approximately 40-60%) of sleep apnea 
syndrome (SAS) in PD patients (N. J. Diederich et al., 2005; Maria et al., 2003). Upper airway 
muscle dysfunction may have a role in the development of obstructive sleep apnea (Vincken 
et al., 1984). However, recent studies assessing the prevalence of SAS in PD revealed that  
the apnea-hypopnea index was not significantly different between PD patients and controls, 
and the rate of obstructive sleep apnea in PD were similar to that seen in the general 
population (De Cock et al., 2010; Trotti & Bliwise, 2010). These findings indicate that 
obstructive sleep apnea may be not a relevant issue in PD. Nocturnal stridor caused by vocal 
cord abductor dysfunction can develop in patients with PD but more frequently occurs in 
patients with multiple system atrophy (MSA) (Isozaki et al., 1995). It is important to screen 
for vocal cord abductor dysfunction with a laryngoscopy during sleep when nocturnal 
stridor occurs. Treatment, such as continuous positive airway pressure therapy or a 
tracheotomy, is effective. However, these treatments do not always prevent sudden death in 
patients with MSA, suggesting a mechanism such as central hypoventilation, other than 
upper airway obstruction, may play a role (Shimohata et al., 2008). 
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13. Conclusion 
Sleep disturbances in PD are complicated by various factors. We reviewed the current 
literature regarding nighttime problems in PD. Appropriate evaluation and management of 
nocturnal motor and non-motor symptoms are essential to improve the patient’s quality of 
life. Importantly, several symptoms are responsive to changes in the dose or timing of 
dopaminergic medications. Substantial research effort has been made to develop effective 
treatment for motor symptoms, however, treating non-motor symptoms remains a 
challenging issue.  
14. Appendix 
The Parkinson’s Disease Sleep Scale (Chaudhuri et al., 2002) 
1. The overall quality of your night’s sleep is: 
2. Do you have difficulty falling asleep each night? 
3. Do you have difficulty staying asleep? 
4. Do you have restlessness of legs or arms at night or in the evening causing disruption of 
sleep? 
5. Do you fidget in bed? 
6. Do you suffer from distressing dreams at night? 
7. Do you suffer from distressing hallucination at night (seeing or hearing things that you 
are told do not exist)? 
8. Do you get up at night to pass urine? 
9. Do you have incontinence of urine because you are unable to move due to “off” 
symptoms? 
10. Do you experience numbness or tingling of your arms or legs which wake you from 
sleep at night? 
11. Do you have painful muscle cramps in your arms or legs whilst sleeping at night? 
12. Do you wake early in the morning with painful posturing of arms or legs? 
13. On waking do you experience tremor? 
14. Do you feel tired and sleepy after waking in the morning? 
15. Have you unexpectedly fallen asleep during the day? 
Scores for a given individual item range from 0 to 10: 10 represents the best, 0 represents the 
worst score. For question 1: Awful = 0, Excellent = 10. For question 15: Frequently = 0,  
Never = 10. For the remainder of the questions: Always = 0, Never = 10. 
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